Synapse - Dean Bajorin

Results (660)

Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057

Meeting Abstract

De Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Krieger, L. E. M.; Boormans, J. L.; Roumiguié, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)

Meeting Abstract

Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Hennessy, D.; Manitz, J.; Niegisch, G.; Powles, T.; Rosenberg, J. E.; Bajorin, D. F.; Apolo, A. B.; Pond, G. R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Gupta, S.; Sonpavde, G.; Grivas, P.; Apolo, A. B.; Plimack, E. R.; Flaig, T. W.; Hahn, N. M.; Balar, A. V.; Bajorin, D. F.; Galsky, M. D.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)

Meeting Abstract

Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT)

Meeting Abstract

Dean, L. W.; Wong, N. C.; Dason, S.; Isharwal, S.; Donoghue, M.; Jia, L.; Tap, W. D.; Joseph, G.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration

Meeting Abstract

Funt, S. A.; Solovyov, A.; Faltas, B. M.; Iyer, G.; Boyd, M. E.; Cipolla, C. K.; Regazzi, A. M.; Teo, M. Y.; Lee, C. H.; Al-Ahmadie, H.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

Balar, A. V.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J.; Mourey, L.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma

Meeting Abstract

Almassi, N.; Pietzak, E. J.; Funt, S. A.; Schultz, N.; Dalbagni, G.; Bochner, B. H.; Al-Ahmadie, H.; Bajorin, D. F.; Rosenberg, J. E.; Iyer, G.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save